CFTR Modulators in Cystic Fibrosis (Elexacaftor,Tezacaftor,Ivacaftor)

Introduction and Mechanism of Action

Elexacaftor/tezacaftor/ivacaftor (ETI) constitutes a highly effective CFTR modulator triple therapy (HEMT).
It shifts Cystic Fibrosis (CF) from a progressive fatal disease to a manageable chronic condition by directly addressing the underlying misfolded protein defect.

Modulator	Pharmacological Role
Ivacaftor	Potentiator: Increases the open probability of the CFTR channel at the cell surface.
Tezacaftor	Corrector: Facilitates cellular processing and trafficking of the CFTR protein to the cell membrane.
Elexacaftor	Stabilizer: Further corrects and stabilizes the misfolded CFTR protein.

Approval Criteria: Approved by the FDA and EMA for children $\geq$ 2 years possessing at least one F508del mutation or responsive variants.
Coverage: Recent 2026 label expansions cover 90-95% of CF patients globally.
Initiation: Initiate early at the youngest eligible age without any lung function threshold to maximize benefit.
Monitoring Protocol (CFF 2025): Mandates quarterly surveillance of liver function tests, ophthalmology (for cataracts), and growth parameters.
Drug Interactions: Requires careful monitoring and shared decision-making regarding CYP3A inducers and inhibitors.

Early preschool intervention maximizes benefits by preventing irreversible lung damage and averting frequent hospitalizations.

Clinical Domain	Demonstrated Outcomes (PROMISE & Real-World Studies)
Pulmonary Function	Improves ppFEV1 by 10-14.2%; reduces acute pulmonary exacerbations by 60-65%.
Microbiology	Rapid reduction in Pseudomonas and Aspergillus colonization (61% drop in Aspergillus by Year 2).
Gastrointestinal & Nutritional	Rapid BMI improvement (z-score normalization); improved exocrine pancreatic function and nutrient absorption.
Biochemical Markers	Reduces sweat chloride significantly (average reduction of 50-60 mmol/L).
Therapy De-escalation	Reduces mean chronic supportive therapies (inhaled antibiotics, hypertonic saline, dornase alfa, azithromycin) from 2.6 to 1.4 per patient.

Generally well-tolerated with mild adverse effects like headache and rash occurring in <10% of patients.
Indian pharmacogenetic studies confirm that CYP3A5 variants have minimal impact on ETI response.

Epidemiology: F508del mutation prevalence in India is 25-40%, which is significantly lower than Western populations (70-90%), requiring responsive variant testing for eligibility.
Diagnostic Gaps: Underestimated true incidence (likely 1:10,000–1:40,000 births) limits identification due to delayed diagnosis and minimal neonatal screening.
Access Barriers: Extremely high cost (₹2-3 crore/year) and prolonged patent barriers up to 2037 restrict equitable access.
Policy Integration: Supported under the National Policy for Rare Diseases (NPRD) Group 3, offering financial support up to ₹20 lakh/patient via specialized Centres of Excellence.
Pediatrician's Role: Suspect CF early, confirm via sweat chloride and Next-Generation Sequencing (NGS) genotyping panels, and aggressively advocate for biosimilars or compassionate access programs.